Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy
Key Highlights
- ➤HAE analysis published in Advances in Therapy, evaluating real-world treatment gaps
- ➤1,131 HAE patient records assessed by 225 physicians across U.S., Europe, and Japan
- ➤Patients often left attacks untreated because severity did not justify treatment burden
- ➤Daily oral LTP was preferred over biweekly or monthly injections
- ➤Treatment satisfaction hinged on portability, administration route, efficacy, and adverse-event odds
Expert Statements
Peng Lu, President of Pharvaris
“By incorporating both physician-reported clinical data and patient-reported experiences, this analysis provides a comprehensive view of how hereditary angioedema is managed in routine clinical practice.”
Peng Lu, President of Pharvaris
“Early diagnosis and effective treatment remain critical, yet this real-world analysis highlights remaining gaps between guideline-recommended care and the actual experience of people with HAE.”
Peng Lu, President of Pharvaris
“Addressing these gaps may help improve treatment outcomes, enhance patient satisfaction, and optimize overall disease management.”
Peng Lu, President of Pharvaris
“These findings highlight the importance of understanding how treatment decisions are made in real-world settings and the barriers that may still limit alignment with clinical guidelines.”
Peng Lu, President of Pharvaris
“At Pharvaris, we are committed to supporting the HAE community by leveraging insights to inform decisions and to identify solutions that may further inform medical care and address the practical and clinical needs of patients and physicians in everyday practice.”
ZUG, Switzerland, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS) a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema (AE-BK), such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that insights from a Pharvaris-funded analysis of the multinational Adelphi Real World HAE Disease Specific Programme™ (DSP) dataset evaluating how HAE is managed in clinical practice have been published in Advances in Therapy.
The analysis evaluated real-world patterns of HAE disease management including frequency, severity, and characteristics of HAE attacks; use of long-term prophylaxis (LTP) and on-demand treatment (ODT); patient and physician decision-making around treating or not treating attacks; treatment adherence and reasons for suboptimal adherence; and patient and physician perspectives on treatment satisfaction and unmet needs.
Get started
Create a free account to read the full story.